冠福股份(002102) - 2024 Q2 - 季度业绩预告

Financial Performance - The estimated net profit attributable to shareholders for the first half of 2024 is projected to be between 50 million and 70 million yuan, representing a decline of 76.78% to 83.42% compared to the same period last year, which was 301.52 million yuan [3]. - The estimated net profit after deducting non-recurring gains and losses is expected to be between 45 million and 60 million yuan, a decrease of 55.38% to 66.53% from 134.46 million yuan in the previous year [3]. - The basic earnings per share is projected to be between 0.019 yuan and 0.0266 yuan, down from 0.1145 yuan in the same period last year [3]. Factors Affecting Profit - The decline in profit is attributed to the absence of non-recurring gains from debt resolution in 2023, which amounted to 127 million yuan, and increased estimated liabilities due to ongoing litigation related to information disclosure violations [5]. - The company's subsidiaries are facing intense market competition, leading to a decline in product profitability compared to the previous year, although there is a slight increase in overall revenue [5]. Market Outlook - The market price of the main product, Vitamin E, has shown signs of recovery, which could positively impact the company's performance in the second half of 2024 if the trend continues [6]. - The company is in the process of selling 100% equity of Shanghai Wutian Real Estate Co., Ltd., with an expected transaction price of 800 million yuan, which could contribute approximately 390 million yuan to the company's profits in 2024 [6]. Reporting Notes - The financial data presented is preliminary and subject to confirmation in the official half-year report to be released later [7].